Hepsera tablets 10 mg for chronic hepatitis B (adefovir, Preveon)
Product Code :
Availability : 10
General information on Japanese Hepsera tablets 10 mg for chronic hepatitis B (adefovir, Preveon)
Package details: 30 tablets
Manufacturer: GlaxoSmithKline K.K., Japan
Active ingredients: adefovir pivoxil (chemical formula C20H32N5O8P)
Medical effect: Hepsera tablets are effective for the treatment of chronic hepatitis B virus infection.
Contraindications and precautions: do not use for pregnant or breastfeeding women.
A patient should receive medical examination on a regular basis.
Store away from direct sunlight, heat and moisture.
If an allergic reaction occurs, stop using the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.
Dosage and administration
For adults: take 1tablet (10 mg of adefovir) once a day.
How effective are Hepsera tablets 10 mg from Japan for chronic hepatitis B (adefovir, Preveon)?
Hepsera tablets contain adefovir pivoxil, a prodrug adefovir, a nucleoside reverse transcriptase inhibitor. It works by blocking reverse transcriptase, an enzyme essential for hepatitis B virus to reproduce in the body. Thus, Hepsera tablets suppress the virus growth and improve the liver function.
Who should use Hepsera tablets 10 mg from Japan?
Hepsera tablets are effective for the treatment of chronic hepatitis B virus infection. This medicine helps to reach the following effects:
- histologic improvement,
- reduction in serum HBV DNA levels,
- normalization of alanine aminotransferase levels,
- normalization of HBeAg seroconversion.
Studies also showed that the dosage of 10 mg of adefovir a day is relatively safe, has few adverse effects and the virus is unlikely to develop resistance to it within the first 48 weeks of treatment at least (P. Marcellin, T. T. Chang et al. "Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B". The New England Journal of Medicine, 2003, 348 (9): 808–16).